Abbott Laboratories (ABT)
(Delayed Data from NYSE)
$118.13 USD
+0.50 (0.43%)
Updated Sep 17, 2024 04:01 PM ET
After-Market: $118.13 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
C Value D Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$118.13 USD
+0.50 (0.43%)
Updated Sep 17, 2024 04:01 PM ET
After-Market: $118.13 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
C Value D Growth C Momentum D VGM
Zacks News
Haemonetics (HAE) Q4 Earnings Top Mark, Operating Margin Up
by Zacks Equity Research
A steady momentum in new business wins and consistent geographical expansion drive Haemonetics' (HAE) top-line results
Bruker (BRKR) Q1 Earnings Beat Estimates, Guidance Upbeat
by Zacks Equity Research
Bruker's (BRKR) current focus on product development through higher R&D investment stokes investors' positive sentiment around the stock.
Top Stock Reports for Verizon, Abbott & Illinois Tool Works
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Verizon (VZ), Abbott (ABT) and Illinois Tool Works (ITW).
Henry Schein's (HSIC) Q1 Earnings, Revenues Beat Estimates
by Urmimala Biswas
Henry Schein's (HSIC) strong share gains in the North American market raise optimism.
Intersect (XENT) Q1 Loss Wider Than Estimates, Revenues Top
by Zacks Equity Research
Intersect (XENT) records revenue growth on increased adoption of the PROPEL family of products and SINUVA Sinus Implant.
QIAGEN's (QGEN) Q1 Earnings Top Estimates, Revenues Miss
by Zacks Equity Research
QIAGEN (QGEN) sees year-over-year growth across all segments and majority of geographies.
Masimo (MASI) Q1 Earnings and Revenues Beat, Guidance Solid
by Zacks Equity Research
Solid non-invasive revenues boost Masimo's (MASI) Q1; guidance raised.
Luminex (LMNX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Luminex (LMNX) Q1 results gain from higher revenues from System sales, Royalty as well as Service segments. However, contraction in gross margin remains a woe.
Surmodics (SRDX) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Surmodics (SRDX) consistently gains traction from its core Medical Devices unit, which witnesses a substantial contribution from the SurVeil pact with Abbott.
Fresenius Medical (FMS) Q1 Earnings & Revenues Top Estimates
by Zacks Equity Research
Fresenius Medical (FMS) gains from solid international revenues in Q1.
HMS Holdings' (HMSY) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Top-line growth, higher commercial and state government revenues and expansion in margins aid HMS Holdings (HMSY) in Q1 earnings. However, increase in cost of services remains a woe.
Integer Holdings (ITGR) Q1 Earnings & Revenues Top Estimates
by Zacks Equity Research
Top-line growth and better performance at Medical and Non-Medical segments benefit Integer Holdings' (ITGR) Q1 results. However, contraction in gross margin remains a dampener.
AMN Healthcare (AMN) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Higher revenues and expansion in gross margin find reflection in AMN Healthcare's (AMN) Q1 results. However, weak performance at Nurse and Allied and Locum Tenens segments remain woes.
Is Abbott Laboratories (ABT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (ABT) Outperforming Other Medical Stocks This Year?
Globus Medical (GMED) Q1 Earnings Miss, Revenues Grow Y/Y (Revised)
by Zacks Equity Research
Globus Medical (GMED) management states that the first quarter of a year poses a seasonal challenge to the company's capital equipment, which grossly affects its sales in Q1.
DENTSPLY SIRONA (XRAY) Q1 Earnings & Revenues Top Estimates
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) Q1 earnings gain from Technology & Equipment unit despite international revenues being down.
Insulet (PODD) Beats Earnings and Revenue Estimates in Q1
by Zacks Equity Research
Insulet (PODD) registers year-over-year improvement in revenues on solid uptake of Omnipod system both in the United States and international markets.
Medidata (MDSO) Q1 Earnings Beat Estimates, Margins fall
by Zacks Equity Research
Medidata (MDSO) witnesses year-over-year revenue growth in double-digits across both operating segments in first-quarter 2019.
PRA Health (PRAH) Q1 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
PRA Health's (PRAH) Q1 earnings reflect top-line growth, favorable segmental performance and margin expansion.
Globus Medical (GMED) Q1 Earnings Miss Mark, Margins Weak
by Zacks Equity Research
Globus Medical (GMED) management states that the first quarter of a year poses a seasonal challenge to the company's capital equipment, which grossly affects its sales in Q1.
ResMed's (RMD) Q3 Earnings Beat Estimates, Revenues in Line
by Zacks Equity Research
ResMed (RMD) registers double-digit global revenue growth in Q3 on the back of solid sales from Software-as-a-Service businesses and new mask products plus devices.
Teleflex (TFX) Q1 Earnings Top Estimates, Margins Decline
by Zacks Equity Research
Teleflex (TFX) reports robust improvement in revenues on balanced growth across all segments and geographies.
Cardiovascular Systems (CSII) Q3 Earnings Top, View Tapered
by Zacks Equity Research
Cardiovascular Systems (CSII) rides high on a year-over-year rise in both Coronary and peripheral device revenues.
NuVasive (NUVA) Q1 Earnings Top Estimates, Margins Strong
by Zacks Equity Research
NuVasive's (NUVA) solid international sales in Q1 boost investor confidence in the stock.
DexCom (DXCM) Beats on Q1 Earnings, Hikes '19 Guidance
by Zacks Equity Research
DexCom's (DXCM) Q1 earnings gain from top-line growth and solid segmental performance. However, contraction in gross margin remains a headwind.